PODD: Growth moderates as type 2 retention challenges are addressed and new innovations launch

Guidance was lowered due to higher attrition in type 2 diabetes, but corrective actions and a robust innovation pipeline are expected to drive future growth. U.S. and international growth rates will moderate, with stable pricing and continued investment in operational scale and new product launches…